User profiles for SHAHROKH F. SHARIAT

Shahrokh F. Shariat, MD

Department of Urology, Comprehensive Cancer Center, Medical University of Vienna and …
Verified email at meduniwien.ac.at
Cited by 99047

Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration

V Margulis, SF Shariat, SF Matin, AM Kamat… - Cancer, 2009 - Wiley Online Library
BACKGROUND: The literature on upper tract urothelial carcinoma (UTUC) has been limited
to small, single center studies. A large series of patients treated with radical …

European Association of Urology guidelines on non–muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)

…, J Palou, BWG van Rhijn, M Rouprêt, SF Shariat… - European urology, 2022 - Elsevier
Context The European Association of Urology (EAU) has released an updated version of
the guidelines on non–muscle-invasive bladder cancer (NMIBC). Objective To present the …

EAU guidelines on non–muscle-invasive urothelial carcinoma of the bladder: update 2016

…, J Palou, M Rouprêt, BWG van Rhijn, SF Shariat… - European urology, 2017 - Elsevier
Context The European Association of Urology (EAU) panel on Non–muscle-invasive
Bladder Cancer (NMIBC) released an updated version of the guidelines on Non–muscle-invasive …

EAU guidelines on non–muscle-invasive urothelial carcinoma of the bladder: update 2013

M Babjuk, M Burger, R Zigeuner, SF Shariat… - European urology, 2013 - Elsevier
Shahrokh F. Shariat is a company consultant for Ferring Pharmaceuticals and participates
in trials for Alere Inc. on NMP22. He is the inventor or co-inventor of the following patents: …

European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2020 update

…, RJ Sylvester, BWG Van Rhijn, R Zigeuner, SF Shariat - European urology, 2021 - Elsevier
… Burger d , Otakar Capoun e , Daniel Cohen f , Eva M. Compérat g , Nigel C. Cowan h , Jose
L. … Sylvester n , Bas WG van Rhijn d o , Richard Zigeuner p , Shahrokh F. Shariat b q r s t …

European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)-2019 update

…, J Palou, BWG van Rhijn, M Rouprêt, SF Shariat… - European urology, 2019 - Elsevier
Shariat a b j k l , Richard Sylvester m , Richard Zigeuner n , Otakar Capoun o † , Daniel
Cohen p † , José Luis Dominguez Escrig q † , Virginia Hernández r † , Benoit Peyronnet s † , …

[HTML][HTML] Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma

…, Y Tomita, A Bamias, T Lebret, SF Shariat… - … England Journal of …, 2021 - Mass Medical Soc
Background The role of adjuvant treatment in high-risk muscle-invasive urothelial
carcinoma after radical surgery is not clear. Methods In a phase 3, multicenter, double-blind, …

Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium

SF Shariat, PI Karakiewicz, GS Palapattu… - The Journal of …, 2006 - auajournals.org
Purpose : We present the characteristics and outcomes of a large, contemporary, consecutive
series of patients treated with radical cystectomy and pelvic lymphadenectomy for …

European association of urology guidelines on upper urinary tract urothelial carcinoma: 2017 update

…, BWG Van Rhijn, AH Mostafid, J Palou, SF Shariat - European urology, 2018 - Elsevier
Shahrokh Shariat owns or co-owns the following patents: Shariat S, Slawin K. Methods to
determine prognosis after therapy for prostate cancer. US patent 60/266,976. …

Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy

AJ Stephenson, SF Shariat, MJ Zelefsky, MW Kattan… - Jama, 2004 - jamanetwork.com
ContextSalvage radiotherapy may potentially cure patients with disease recurrence after
radical prostatectomy, but previous evidence has suggested that it is ineffective in patients at …